Industry Response Time Is Contributing To Slower Drug Approvals, FDA Says
Executive Summary
Industry response time is contributing to the increase in FDA drug approval times, Office of Review Management Special Assistant to the Director Kim Colangelo told the Regulatory Affairs Professionals Society's annual conference in Baltimore Nov. 7
You may also be interested in...
PDUFA III “Good Review Management Principles” To Stress Early Action
FDA's "Good Review Management Principles" guidance will recognize the need for the completion of second- and third-round reviews of NDAs and BLAs before the action goal date under the Prescription Drug User Fee Act III
PDUFA III “Good Review Management Principles” To Stress Early Action
FDA's "Good Review Management Principles" guidance will recognize the need for the completion of second- and third-round reviews of NDAs and BLAs before the action goal date under the Prescription Drug User Fee Act III
FDA Drug Approval Time Edges Up To 18.5 Months In 2001
The average NDA approval time is still about a year and a half, an analysis of new molecular entities cleared by FDA in 2001 shows